Table 4.
Comparison of medications received by patients in treatment vs. control groups (n = 135).
| Variables | Treatment group (n = 27) | Control group (n=108) | p-value |
|---|---|---|---|
| Number (%) or Median (IQR) | |||
| Continuous albuterol | |||
| Duration (days) | 2.08 (1.00–5.33) | 0.69 (0.42–1.38) | <0.01a |
| CORTICOSTEROIDS | |||
| Agents | |||
| Methylprednisolone | 27 (100) | 106 (98.2) | 1.00b |
| Prednisolone | 11 (40.7) | 46 (42.6) | 0.86c |
| Prednisone | 9 (33.3) | 41 (38) | 0.66c |
| Dexamethasone | 4 (14.8) | 26 (24.1) | 0.30c |
| Hydrocortisone | 1 (3.7) | 2 (1.9) | 0.49c |
| Methylprednisolone IV frequency | |||
| Every 6 h | 23 (85.2) | 57 (53.8) | 0.01c |
| Every 8 h | 2 (7.4) | 8 (7.6) | |
| Every 12 h | 1 (3.7) | 38 (35.9) | |
| Every 24 h | 1 (3.7) | 3 (2.8) | |
| Dosing regimen | |||
| Duration (days) | 5.4 (3.6–10.3) | 2.5 (1.8–3.9) | <0.01a |
| Cumulative dose in mgd | 693.8 (426.0–1,350.0) | 306.3 (178.8–452.5) | <0.01a |
| Cumulative dose in mg/kgd | 19.0 (13.1–41.3) | 7.89 (5.73–11.7) | <0.01a |
| Daily dose in mg/kg/dayd | 3.8 (2.7–4.4) | 3.0 (2.3–4.0) | 0.02a |
| ADVANCED THERAPIES OTHER THAN MAGNESIUM SULFATE | |||
| Ketamine | |||
| Received ketamine | 11 (40.7) | 16 (14.8) | <0.01c |
| Duration (days) | 2.5 (0.6–6.0) | 1 (0.6–1.3) | 0.15a |
| Terbutaline | |||
| Received terbutaline | 12 (44.4) | 8 (7.4) | <0.01b |
| Duration (days) | 2.81 (0.83–3.88) | 0.75 (0.21–0.88) | 0.01a |
| Aminophylline | |||
| Received aminophylline | 12 (44.4) | 3 (2.8) | <0.01b |
| Duration (days) | 2.27 (1.29–5.17) | 0.96 (0.21–1.38) | 0.07 |
| Heliox | 3 (11.1) | 2 (1.9) | 0.05 |
| Number of advanced therapies administered | –e | ||
| Zero | – | 86 (79.6) | |
| One | 11 (40.7) | 18 (16.7) | |
| Two | 4 (14.8) | 3 (2.8) | |
| Three | 5 (18.5) | 1 (0.9) | |
| Four | 7 (25.9) | 0 (0) | |
IQR, Interquartile range.
a
Wilcoxon two-sample test.
b
Fisher's Exact test.
c
Chi-square test.
d
Calculated as prednisone equivalent dose.
e
Statistical analysis was not applicable.
fExact Chi-square test.